scarletred
Home
Company
Products
Scarletred
®Vision
Scarletred
®Telemedicine
Services
Applications
CAREER
News
Contact
Menu
01
Home
02
Company
03
Products
04
Services
05
Applications
06
News
07
Contact
Get in touch
Austria
SCARLETRED Holding GmbH
MQM 3.4, Maria Jacobi Gasse 1,
8th floor, 1030 Vienna, Austria
USA
SCARLETRED Inc.
1 Broadway, 14th floor,
Cambridge, MA 02142, USA
office@scarletred.com
Privacy Policy
Social
Linkedin
Linkedin
Linkedin
Twitter
Instagram
Instagram
Facebook
Facebook
info
Press
Career
FAQ
Regulatory
Imprint
Scarletred
Keywords:
#
AAD 2024
#
Tissue Classifier
#
Conferences
#
Skin Care
#
AAD 2023
#
BioJapan2022
#
JAK inhibitors
News
•
May 6, 2022
SCARLETRED's CFO at the Think Tank discussion at the Global Female Leaders Summit 2022
After 3 years, the well-renowned women's conference, Global Female Leaders Summit, will take place from the 8th-10th of May 2022 at the Adlon Hotel Kempinski in Berlin, Germany.
News
•
Mar 1, 2022
Meet SCARLETRED at the 3rd Dermatology Drug Development Europe Summit
Following a successful launch in Europe in 2019, and a tremendous online experience in 2021, the 3rd Dermatology Drug Development Europe Summit, returns in April 2022 in Frankfurt, Germany.
News
•
Dec 14, 2021
SCARLETRED's digital solution for vaccine development featured in the business magazine “Gewinn”
The business magazine Gewinn discusses how Scarletred®Vision is an excellent addition to the safety and monitoring of injection site reactions (ISRs) in vaccine development.
News
•
Nov 17, 2021
SCARLETRED’s eHealth milestones featured in Austrian Newspaper “Der Standard”
The popular newspaper Der Standard features the recent milestones of SCARLETRED in the field of teledermatology. With these, SCARLETRED sets the benchmark for AI-Assisted Screening in telemedicine and radiation oncology.
News
•
Nov 15, 2021
Dermatology & disease management: An interview with an expert about the applications of SCARLETRED
In an interview, specialist Dr. Zikeli discusses the clinical characteristics of atopic dermatitis and why documentation using Scarletred®Vision is an optimal support for diagnosis and progress monitoring.
News
•
Oct 19, 2021
SCARLETRED at the 5th Annual Dermatology Drug Development Summit
The 5th Annual Dermatology Drug Development Summit focusing on development and innovation of therapies and research targeting inflammatory skin diseases, returns to Boston for 2021.
News
•
Oct 15, 2021
Meet SCARLETRED at the 4th Inflammatory Skin Disease Summit
The Inflammatory Skin Disease Summit is a jointly organized event by the Icahn School of Medicine at Mount Sinai and the Austrian Academy of Sciences.
News
•
Sep 27, 2021
The Evolution of SCARLETRED and Artificial Intelligence Assisted Screening in Teledermatology
The clinically validated and award-winning technology, Scarletred®Vision, is on market since 2015, enabling high quality remote skin imaging and objective analysis in over 3000 cutaneous disorders.
News
•
Sep 21, 2021
SCARLETRED at Round-Table Discussion of Börse Express about Life Science Industry in Austria
In the round table discussion of the leading financial domain Börse Express, Marinomed, Scarletred, PHH Rechtsanwälte, and EOSS Industries discussed the development and hurdles of Austrian life science start-ups.
News
•
Jul 27, 2021
SCARLETRED represents Austrian eHealth at the upcoming World EXPO in Dubai
The EXPO 2020 “Connecting Minds, Creating the Future” theme addresses visions of a more networked and technology-based future, covering topics from smart city over sustainability to digital healthcare.
News
•
Nov 26, 2020
Student team winning 3rd place with Scarletred’s challenge on WSA Youth for Innovation program
International team of four talented students has won a 3rd place on WSA Youth for Innovation case study competition by solving Scarletred´s challenge on injection site reactions.
News
•
Sep 1, 2020
Houskapreis 2020: SCARLETRED is nominated for Austria's largest private research award
The research award has been awarded annually by the B&C Private Foundation. With the Houska Prize, the B&C private foundation is committed to improving research conditions and cutting-edge research in Austria.
News
•
May 11, 2020
Stadt Wien zündet den 5G Turbo: 20 Mio. Euro für raschen Ausbau
Wien (OTS) - Videokonferenzen, Home Schooling, Online-Yogastunden – die aktuelle Corona-Situation hat eindrücklich bewiesen, wie wichtig digitale Kommunikation für alle Lebensbereiche geworden ist.
News
•
May 5, 2020
Modern telemedicine for suspected corona cases: SeneCura uses the Scarletred app "eCOVID19"
SeneCura is currently using the CE-certified medical device of Scarletred in eleven care facilities, after which a roll-out to every SeneCura facilities in Austria is planned.
News
•
Mar 13, 2020
Houskapreis 2020: SCARLETRED nominiert für Österreichs größten privaten Forschungspreis
Der Houskapreis ist Österreichs größter privater Forschungspreis. Insgesamt 500.000 Euro vergibt die B&C Privatstiftung für Spitzenforschung aus Österreich.
News
•
Jan 18, 2020
Winner 5G Use Case Challenge
Following a call from the City of Vienna for 5G use case entries in autumn 2019, Azoome and Scarletred, with A1 as their technology partner, have won awards for education and healthcare. Funded pilots will begin this year.
News
•
Jan 12, 2020
Winner of the TechBIZKON III Award in Japan
Last week SCARLETRED won the Japanese TechBIZKON – Digital Health beyond 2020 Award! We want to say thanks to the audience for their strong vote and to EDGEof for making this great digital health event possible.
News
•
Jan 9, 2020
WSA IMPACT STORIES – SCARLETRED
In 2014, while conducting a clinical trial, Dr. Harald Schnidar percieved the need of a technology that allows to objectify dermatological assessments. Reacting to the lack of a suitable solution, he founded SCARLETRED.
News
•
Nov 18, 2019
Ranked in Top-10 of young entrepreneurs in Austria
The GEWINN YOUNG ENTREPRENEUR competition took place for the 30th time, there were about 1,000 first registrations, of which 300 were judged and we are happy to say that SCARLETRED was positioned 7th in the final 100!
Article
•
Aug 14, 2023
SCARLETRED skin monitoring helps to make treatments with JAK inhibitors safer
With patient safety in mind, SCARLETRED®Vision can be used as a digital aid to measure and document treatment safety and efficacy of newly developed JAK inhibitors either on site and/or home based clinical trials.
Article
•
Jul 31, 2023
Hidradenitis Suppurativa - Pharma Goes Digital to Accelerate Clinical Drug Development
Hidradenitis suppurativa (HS) is an autoinflammatory skin condition that causes abscesses and scarring on the skin and affects about 1-4% of the total population (Ballard & Schuman, 2020).
Article
•
Jul 10, 2023
Atopic Dermatitis - in the New Age of Digital Dermatology
People suffering from atopic dermatitis struggle with the condition itself and stigmatization, making digital analysis of disease and treatment vital to clinical management to enhance their quality of life using SCARLETRED.
Article
•
Mar 8, 2023
Epidermolysis Bullosa - How Does Remote Wound Care in Rare Skin Diseases Work?
SCARLETRED’s certified medical device provides medical professionals with a novel digital solution to allow them to assess and analyze the individuals’ affected areas in an accurate, time-efficient, and user-friendly manner.
Article
•
Jun 16, 2021
Evaluation of Treatment Efficacy through Skin Texture Analysis
The traditional assessment of skin texture based on multiple health professionals can lead to inconsistent results making standardized digital dermatological monitoring, as provided by SCARLETRED, an essential tool.
Article
•
May 18, 2021
Psoriasis - Dermatologists Get a Major Technology Upgrade
Psoriasis is a chronic inflammatory disease of the skin associated with red, raised plaques and scaly skin. Psoriasis is a global problem affecting approximately 2-3% of the total population.
Article
•
May 11, 2021
Electronic Patient Reported Outcome (ePRO) Gains Momentum in Clinical Trials
Patient-reported outcome (PRO) refers to a health outcome directly based on patient self-reporting. While some measures can be captured during site visits, others may be tracked more efficiently close to real-time.
Article
•
Apr 27, 2021
Scarletred®Vision: A Scalable Digital Solution for Measurement of the Individual Typology Angle (ITA°) and Changes in the Skin Tone
SCARLETRED’s mobile technology, Scarletred®Vision, provides clinically validated R&D tools to document, analyse, and monitor skin color and pigmentation variations in multi-centric or home based cosmetics studies.
Article
•
Apr 8, 2021
Onychomycosis: Quantifying Healthy vs. Infected Nail Areas
Onychomycosis is an infection of the nail caused by fungal organisms. With SCARLETRED’s digital technology, experts can quantify and monitor disease progression allowing for consistent and personalized treatment.
Article
•
Mar 23, 2021
Rosacea Objective Standardized Analysis: Quantitative Assessment of Erythema and Skin Texture Alterations
Being a chronic inflammatory skin disorder, patients with rosacea need standardized tools, as provided by SCARLETRED, to improve the condition’s analysis and treatment and overcome psychosocial stigmatization.
Article
•
Feb 10, 2021
Vaccination - Monitoring of Injection Site Reactions
Standardized documentation and scoring of injection site reactions is a crucial part of clinical trials, as local development of skin erythema can reflect on the effectiveness and side effects of an investigational product.
Article
•
Nov 2, 2020
Skin Cancer - Standardized Assessment Through Digital Technology
Skin cancer is one of the most common types of cancer but also the most preventable one. The incidence rates for non-melanoma skin cancer drastically increased, and currently, there are 2-3 million cases each year.
Article
•
Oct 20, 2020
Solar Lentigo - Standardized Measurement of Age Spots
Solar lentigo, also called age spots, is a common form of hyperpigmentation, especially in adults older than 50, caused by natural or artificial ultraviolet light exposure.
Article
•
Oct 13, 2020
Vitiligo - Revolutionizing Dermatology by Standardized Assessment
Vitiligo is a long-term pigmentation disorder affecting 0.5 - 1% of individual. SCARLETRED is revolutionizing dermatology by allowing the standardization of the assessment and monitoring of vitiligo.
Article
•
Oct 5, 2020
Objective Measurement of Skin Pigmentation Disorders
The skin is the primary interface between nurse and patient. With SCARLETRED, pigmentation disorders can be objectively monitored, improving dermatological and cosmetic dermatological services.
Article
•
Aug 31, 2020
Chronic Wounds - Objective Telemedicine and Remote Wound Care 2.0 Made in Austria
Chronic wound is a medical condition, affecting up to 4% of all people worldwide. The wound care market is one of the biggest in the healthcare system globally, standing now at approx. USD 10.4 billion.
Article
•
Aug 21, 2020
Mobile Wound Care - A Novel Digital Solution for Wound Management
Non-healing wounds pose a significant challenge in clinical medicine and present severe difficulties to millions of patients worldwide. The management of chronic wounds remains a challenging task in terms of their assessment.
Article
•
Aug 3, 2020
Virtualization - The Golden Age of Home-Based Trials has Started
Due to the COVID-19 pandemic, researchers need to adjust clinical trial setups due to the stay-at-home orders and risk of virus transmission. The golden time of virtual and home-based clinical trials has started.
Article
•
Jul 28, 2020
Digital Momentum in Preclinical Drug Screening and Safety Assessment
The current COVID-19 pandemics forced many clinical trials to grind to a halt, stalling research until restrictions are lifted. Scarletred offers a solution for the documentation and monitoring of changes on the skin surface.
Paper
•
November 30, 2023
Automated Classification of Hidradenitis Suppurativa Disease Severity by Convolutional Neural Network Analyses Using Calibrated Clinical Images
Read more